REDWOOD CITY, Calif. – Biotricity, a provider of biometric remote monitoring solutions, has received clearance from the U.S. Food and Drug Administration for its Bioflux mobile electrocardiogram device. The technology enables physicians to remotely monitor and diagnose patients with cardiovascular coronary heart disease by detecting and transmitting probable arrhythmias, along with other diagnostic heart information. “We are ready to hit the ground running,” said Waqaas Al-Siddiq, founder and CEO of Biotricity, in a statement. “With our manufacturing infrastructure fully developed, we expect to be able to bring the Bioflux solution to market imminently.” He said the company plans to develop other disease specific remote biometric technologies to diagnose, treat and manage chronic conditions.
You are here: / / FDA clears Bioflux mobile ECG device for production